Muro, Kei http://orcid.org/0000-0002-5572-743X
Kojima, Takashi
Moriwaki, Toshikazu
Kato, Ken
Nagashima, Fumio
Kawakami, Hisato
Ishihara, Ryu
Ogata, Takashi
Satoh, Taroh
Iwakami, Keiichi
Han, Shirong
Yatsuzuka, Naoyoshi
Takami, Tomoko
Bhagia, Pooja
Doi, Toshihiko
Funding for this research was provided by:
merck sharp & dohme corp., a subsidiary of merck & co., inc.
Article History
Received: 9 July 2021
Accepted: 30 August 2021
First Online: 30 September 2021
Declarations
:
: The study protocol and all amendments were approved by the appropriate ethics committee at each center. The study was conducted in accordance with the protocol, its amendments, and standards of Good Clinical Practice. All patients provided written informed consent.
: Kei Muro reports Grants (to his institution and himself) from Astellas, Amgen, Daiichi Sankyo, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Merck Serono, Ono, Parexel International, Pfizer, Sanofi, Solasia Pharma, and Taiho; consulting fees from Amgen, AstraZeneca, and Ono; honoraria from Bayer, BMS, Chugai, Eli Lilly, Ono, Sanofi, Taiho, and Takeda. Takashi Kojima reports Grant, consulting fee or honorarium, and support for travel to meetings for the study or other purposes from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA for this publication; consultancy for Astellas Pharma, BMS, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Ono Pharmaceutical; Grants from Astellas, Amgen, BioPharma, Shionogi, and Taiho Pharmaceutical; payment for lectures including service on speakers bureaus from Oncolys BioPharma and Ono Pharmaceutical. Toshikazu Moriwaki reports Grants from Chugai Pharmaceutical, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, and Yakult Honsha; payment for lectures including service on speakers bureaus from Bayer, Chugai Pharmaceutical, Eli Lilly, Sanofi, Taiho Pharmaceutical, Takeda Pharmaceutical, and Yakult Honsha. Ken Kato reports researching funding from BeiGene, BMS, Chugai, Merck Biopharma, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Oncolys Biopharma, Ono, and Shionogi. Fumio Nagashima reports Grants from AstraZeneca, Bayer, Chugai, Daiichi Sankyo, Eli Lilly Japan, Eisai, J-Pharma, Japan Clinical Research Support Unit, Kyowa Hakko Kirin, Merck Biopharma, Mochida, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, NanoCarrie, Ono, Pfizer, Sanofi, Sumitomo Dainippon Pharma, Taiho, Takeda, and Yakult; payment for lectures including service on speakers bureaus from Chugai, Kyowa Hakko Kirin, Merck Biopharma, Ono, Sanofi, Shionogi, Sumitomo Dainippon Pharma, Taiho, Takeda, and Yakult. Hisato Kawakami reports Grants/research funding from Chugai/Roche, Daiichi Sankyo, and Eisai; advisory role, honoraria (speeches) from BMS Japan, Daiichi Sankyo, Lilly Japan, Ono Pharmaceutical, and Taiho Pharmaceutical; honoraria (speeches) from AstraZeneca, Bayer, Merck Serono, MSD KK, Takeda, and Yakult Pharmaceutical. Ryu Ishihara has nothing to disclose. Takashi Ogata has nothing to disclose. Taroh Satoh reports Grants from Astellas, BMS, Daiichi Sankyo, Gilead Sciences, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Parexel; endorsed department for Chugai Pharmaceutical, Ono Pharmaceutical, and Yakult Honsha; payment for lectures including service on speakers bureaus (honoraria) from BMS, Chugai Pharmaceutical, Eli Lilly, and Ono Pharmaceutical; and consulting fee from Takara-Bio. Keiichi Iwakami is an employee of MSD K.K., Tokyo, Japan. Shirong Han is an employee of MSD K.K., Tokyo, Japan. Naoyoshi Yatsuzuka is an employee of MSD K.K., Tokyo, Japan. Tomoko Takami is an employee of MSD K.K., Tokyo, Japan. Pooja Bhagia is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Tashihiko Doi reports Grants from AbbVie, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eisai, Janssen, Lilly, Merck Serono, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Novartis, Pfizer, Quintiles, Sumitomo Dainippon, and Taiho; and personal fees from AbbVie, Amgen, Astellas, Bayer, BMS, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, Lilly, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Novartis, Oncolys Biopharma, Ono Pharmaceutical, Rakuten Medical, Sumitomo Dainippon, Taiho, and Takeda.